Prelude Therapeutics Inc (PRLD) Stock Analysis

Prelude Therapeutics Inc (PRLD) is a publicly traded company in the HEALTHCARE sector. It trades at $3.50, carries a market capitalization of $312.21M. This page summarizes the public market data, fundamentals, and frequently asked questions for PRLD, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Prelude Therapeutics Inc currently has a Bullish sentiment score of 0.19.

About Prelude Therapeutics Inc

Prelude Therapeutics Inc. is a clinical-stage oncology firm headquartered in Wilmington, Delaware, dedicated to the development of precision small molecule therapies targeting pivotal cancer drivers. The company boasts a promising pipeline, underpinned by its proprietary drug discovery platform, which aims to deliver innovative treatment solutions for patients with advanced malignancies. With an emphasis on precision medicine, Prelude is strategically positioned to make significant contributi...

GNG Research Analysis

GNG Research scores Prelude Therapeutics Inc (PRLD) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PRLD.

Frequently Asked Questions

Does PRLD pay dividends?

Prelude Therapeutics Inc (PRLD) does not currently pay a regular dividend.

What is PRLD's market cap?

Prelude Therapeutics Inc (PRLD) has a market capitalization of $312.21M with a current stock price of $3.50.